Product
VGX-3100
5 clinical trials
15 indications
Indication
Vulvar DysplasiaIndication
Vulvar Intraepithelial NeoplasiaIndication
VIN2Indication
Human PapillomavirusIndication
Cervical Intraepithelial NeoplasiaIndication
HSILIndication
Anal NeoplasmIndication
Anal Intraepithelial NeoplasiaIndication
HIVIndication
Human Papillomavirus-16 PositiveIndication
Human Papillomavirus-18 PositiveClinical trial
Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSILStatus: Completed, Estimated PCD: 2022-08-23
Clinical trial
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the VulvaStatus: Completed, Estimated PCD: 2020-07-23
Clinical trial
A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2Status: Completed, Estimated PCD: 2020-06-16
Clinical trial
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the CervixStatus: Completed, Estimated PCD: 2020-07-08
Clinical trial
A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive IndividualsStatus: Active (not recruiting), Estimated PCD: 2029-09-20